Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A recombinant, membrane-acting immunotoxin.

A Chovnick1, W P Schneider, J Y Tso

  • 1Protein Design Labs, Mountain View, California 94043.

Cancer Research
|January 15, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Efficacy of free perforator flap combined with great toe transplantation in repairing thumb damage combined with thermal crush injuries in the hand].

Zhonghua shao shang yu chuang mian xiu fu za zhi·2025
Same author

Assessment of angiographic vascularity of meningiomas with dynamic susceptibility contrast-enhanced perfusion-weighted imaging and diffusion tensor imaging.

AJNR. American journal of neuroradiology·2013
Same author

Solitary intraventricular tuberculoma in adults.

Acta neurochirurgica·2005
Same author

Effects of heat, acid, and freeze-thaw challenges on survival of starved Vibrio parahaemolyticus in minimal salt medium, tryptic soy broth, and filtered oyster homogenate medium.

Journal of food protection·2004
Same author

Lateralization and prognostic value of proton magnetic resonance spectroscopy in patients with intractable temporal lobe epilepsy.

Chang Gung medical journal·2002
Same author

Proton magnetic resonance spectroscopy of cerebral glioma after irradiation.

Chang Gung medical journal·2002
Same journal

CDK2 Inhibition Exerts RB-Independent Antitumor Activity in CDK4/6 Inhibitor-Resistant HR+/HER2- Breast Cancer.

Cancer research·2026
Same journal

A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies.

Cancer research·2026
Same journal

Editor's Note: Heterodimerization of Insulin-like Growth Factor Receptor/Epidermal Growth Factor Receptor and Induction of Survivin Expression Counteract the Antitumor Action of Erlotinib.

Cancer research·2026
Same journal

Editor's Note: Deguelin Analogue SH-1242 Inhibits Hsp90 Activity and Exerts Potent Anticancer Efficacy with Limited Neurotoxicity.

Cancer research·2026
Same journal

Retraction: Two Functional Epitopes of Pigment Epithelial-Derived Factor Block Angiogenesis and Induce Differentiation in Prostate Cancer.

Cancer research·2026
Same journal

Editor's Note: Chronic Stress Facilitates Lung Tumorigenesis by Promoting Exocytosis of IGF2 in Lung Epithelial Cells.

Cancer research·2026
See all related articles

Researchers created a novel immunotoxin by linking Clostridium perfringens phospholipase C (PLC) to an anti-Tac antibody fragment. This targeted therapy effectively inhibited protein synthesis in cells expressing the interleukin 2 receptor.

Area of Science:

  • Immunology
  • Molecular Biology
  • Biotechnology

Background:

  • The anti-Tac antibody targets the p55 chain of the human interleukin 2 receptor.
  • Immunotoxins combine targeting moieties with cytotoxic agents for targeted therapy.

Purpose of the Study:

  • To develop a recombinant immunotoxin by genetically linking Clostridium perfringens phospholipase C (PLC) to the anti-Tac antibody's Fab domain.
  • To assess the efficacy of the novel immunotoxin in inhibiting protein synthesis in interleukin 2 receptor-expressing cells.

Main Methods:

  • Genetic fusion of the PLC gene to the anti-Tac heavy chain gene (VHCH1 segment).
  • Co-expression of the anti-Tac light chain gene with a bacterial signal sequence.
  • Secretion of the recombinant immunotoxin, anti-Tac(Fab)-PLC, from transformed Escherichia coli.

Related Experiment Videos

Main Results:

  • The recombinant immunotoxin, anti-Tac(Fab)-PLC, was produced in an active form.
  • Anti-Tac(Fab)-PLC demonstrated binding to cells expressing the interleukin 2 receptor.
  • The immunotoxin potently inhibited protein synthesis with a 50% inhibitory concentration (IC50) of 0.02 nM (1.8 ng/ml).

Conclusions:

  • A functional recombinant immunotoxin, anti-Tac(Fab)-PLC, was successfully engineered.
  • The immunotoxin exhibits specific targeting and potent cytotoxic activity against interleukin 2 receptor-expressing cells.
  • This approach holds potential for targeted cancer therapy by leveraging specific receptor interactions.